Stockscreener 앱 받기
11.06
3.07%
-0.35
시간 외 거래:
10.85
-0.21
-1.90%
전일 마감가:
$11.41
열려 있는:
$11.26
하루 거래량:
171.91K
Relative Volume:
0.72
시가총액:
$109.72M
수익:
$6.39M
순이익/손실:
$-117.26M
주가수익비율:
-0.8862
EPS:
-12.4807
순현금흐름:
$-79.08M
1주 성능:
-3.83%
1개월 성능:
-5.47%
6개월 성능:
-69.32%
1년 성능:
-53.37%
1일 변동 폭
$10.91
$11.40
1주일 범위
$10.91
$14.79
52주 변동 폭
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
명칭
Korro Bio Inc
전화
617-468-1999
주소
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
11.06 | 113.19M | 6.39M | -117.26M | -79.08M | -12.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-11-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Raymond James | Strong Buy |
| 2024-08-14 | 개시 | William Blair | Outperform |
| 2024-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2024-02-27 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-04 | 개시 | H.C. Wainwright | Buy |
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-10 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-01-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 개시 | Cowen | Outperform |
| 2019-10-28 | 개시 | Goldman | Buy |
| 2019-10-28 | 개시 | JP Morgan | Overweight |
모두보기
Korro Bio Inc 주식(KRRO)의 최신 뉴스
Energy Moves: Will Korro Bio Inc stock hit new highs in YEAR2026 Geopolitical Influence & High Return Trade Opportunity Guides - baoquankhu1.vn
Korro Bio, Inc. (KRRO) reports Q4 loss, lags revenue estimates - MSN
Korro Bio raises $85 million in private equity financing By Investing.com - Investing.com Nigeria
Korro Bio Stock Gains After Tough 2025New Drug Candidate, Analyst Upgrades Boost Outlook - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
RBC Capital Keeps Their Hold Rating on Korro Bio (KRRO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Korro Bio (KRRO), Health Catalyst (HCAT) - The Globe and Mail
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability - simplywall.st
Korro Bio (KRRO) sellers register 7.65M common shares after $85M private placement - Stock Titan
Cantor Fitzgerald raises Korro Bio stock price target on UCD confidence - Investing.com Canada
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot - Investing.com Nigeria
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot By Investing.com - Investing.com Australia
Insider Buying: New Enterprise Associates 17, L.P. Acquires Addi - GuruFocus
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Korro Bio investor buys $2.3 million in KRRO stock By Investing.com - Investing.com
Advancing Genetic Medicines with RNA Editing: Inside the OPERA Platform and Therapeutic Strategies - Minichart
Baskett Forest buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million By Investing.com - Investing.com South Africa
Korro Bio (KRRO) major holder adds stock and pre-funded warrants in March 2026 buy - Stock Titan
Insider fund tied to Carmen Chang boosts Korro Bio (KRRO) stake with 450,045 buys - Stock Titan
Korro 10-K: $6.4M Collaboration Revenue; $(12.48) EPS on $(117.3)M Net Loss - TradingView
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
Korro Bio, Inc. (KRRO) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Korro shares jump 17% following $85M private placement financing - MSN
Korro Bio (KRRO) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Korro Secures $85M Lifeline After Trial Setback - National Today
Korro Bio Raises $85 Million in Oversubscribed PIPE Financing to Advance RNA Editing Therapies and Extend Cash Runway into 2028 - Minichart
Korro Bio extends cash runway after trial fail, layoffs - The Business Journals
Korro Announces $85 Million Private Placement - citybiz
Korro Bio prices 4.5M shares at $11.11 in private placement - TipRanks
Korro Announces Oversubscribed $85 Million Private Placement - Bitget
Korro stock surges 17% on $85M private placement financing By Investing.com - Investing.com Canada
Korro Bio Announces Oversubscribed $85M PIPE Financing - TipRanks
Korro Bio raises $85 million in private equity financing - Investing.com
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
Korro stock surges 17% on $85M private placement financing - Investing.com
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan
Investors pour $85M into RNA editor Korro Bio’s genetic disease drugs - Stock Titan
Korro Bio, Inc. $KRRO Stock Position Raised by JPMorgan Chase & Co. - MarketBeat
Bond Watch: Does Korro Bio Inc have pricing powerJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
Winners Losers: Should you avoid Korro Bio Inc stock right nowWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Korro Bio Inc (KRRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):